Maplight Therapeutics (MPLT) Stock Price, News & Analysis

Company Overview

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company’s research is centered on therapies designed to address underlying dysfunction in brain circuits and improve symptoms associated with serious conditions affecting the central nervous system.

MapLight is advancing a pipeline of investigational drug candidates through preclinical and clinical development. Its programs are intended to target significant unmet needs in areas such as schizophrenia and other neuropsychiatric conditions. As with other development-stage biotechnology companies, its products remain subject to clinical testing and regulatory review and may not ultimately receive approval.

The company’s work is primarily focused on drug discovery, clinical research and the development of potential therapies for patients with brain-related disorders. Publicly available information about MapLight’s operating geographies and leadership is limited, so additional company-specific details are not included here.

Key Stats

• Today's Range: $7.44 to $7.81
• 50-Day Range: $7.58 to $13.95
• 52-Week Range: $7.44 to $40.43
• Volume: 394,984 shs
• Average Volume: 367,998 shs
• Market Capitalization: $421.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.50
• Consensus Rating: Moderate Buy

Maplight Therapeutics Stock Analysis - MarketRank™

Maplight Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 245th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Maplight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 4 strong buy ratings, 9 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Maplight Therapeutics has a consensus price target of $29.50, representing about 289.2% upside from its current price of $7.58.

Amount of Analyst Coverage

Maplight Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Maplight Therapeutics are expected to grow in the coming year, from ($5.01) to ($4.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Maplight Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Maplight Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Maplight Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.21% of the float of Maplight Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Maplight Therapeutics has a short interest ratio ("days to cover") of 8.32.

Change versus previous month

Short interest in Maplight Therapeutics has recently increased by 5.54%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maplight Therapeutics does not currently pay a dividend.

Dividend Growth

Maplight Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.71

News Sentiment

Maplight Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Maplight Therapeutics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for MPLT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Maplight Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Maplight Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,267,599.00 in company stock.

Percentage Held by Insiders

3.80% of the stock of Maplight Therapeutics is held by insiders.

Percentage Held by Institutions

Maplight Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MPLT
• CIK: 1770069
• Web: maplightrx.com
• Phone: (650) 839-4360
• Fax: N/A
• Employees: 133
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Maplight Therapeutics: $29.50
• High Price Target: $46.00
• Low Price Target: $13.00
• Potential Upside/Downside: +289.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($42.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$161.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -98.60%
• Return on Assets: -60.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.52
• Quick Ratio: 16.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.10 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 55,576,000
• Free Float: 53,464,000
• Market Cap: $421.27 million
• Optionable: Optionable
• Beta: N/A